Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The Annals of Pharmacotherapy|October 2, 2003
Drug therapy for prevention of recurrent myocardial infarctionMenno E van der Elst, Henk Buurma, Marcel L Bouvy, et al.
Clinical Therapeutics|December 22, 2005
Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysisMenno E van der Elst, Marcel L Bouvy, Cornelis J de Blaey, et al.
Pharmacotherapy|February 10, 2006
Improving pharmacotherapy after myocardial infarction by group academic detailing using feedback data on a patient levelMenno E van der Elst, Marcel L Bouvy, Cornelis J de Blaey, et al.
Heart (British Cardiac Society)|May 16, 2007
Effect of drug combinations on admission for recurrent myocardial infarctionMenno E van der Elst, Marcel L Bouvy, Cornelis J de Blaey, et al.
The Annals of Pharmacotherapy|December 31, 2002
Oral antithrombotic use among myocardial infarction patientsMenno E van der Elst, Nelly Cisneros-Gonzalez, Cornelis J de Blaey, et al.
Expert Opinion on Drug Safety|July 15, 2021
Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle - a focus on benefits and risksLourens T Bloem, Mariana Karomi, Jarno Hoekman, et al.
British Journal of Clinical Pharmacology|November 15, 2021
Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugsLourens T Bloem, Rosa E Bot, Aukje K Mantel-Teeuwisse, et al.
Drug Safety|April 7, 2012
Impact of safety-related regulatory action on clinical practice: a systematic reviewSigrid Piening, Flora M Haaijer-Ruskamp, Jonie T N de Vries, et al.
International Journal of Health Policy and Management|November 2, 2020
The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved DrugsRick A Vreman, Lourens T Bloem, Stijn van Oirschot, et al.
Clinical and Translational Science|March 31, 2021
Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agenciesLourens T Bloem, Rick A Vreman, Niels W L Peeters, et al.
Pageof 2